{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:57:21Z","timestamp":1776419841054,"version":"3.51.2"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100016658","name":"National Plan on Drugs","doi-asserted-by":"publisher","award":["2014\/042"],"award-info":[{"award-number":["2014\/042"]}],"id":[{"id":"10.13039\/100016658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Institute of Health Carlos III","doi-asserted-by":"publisher","award":["RD16\/0017\/0003"],"award-info":[{"award-number":["RD16\/0017\/0003"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Institute of Health Carlos III","doi-asserted-by":"publisher","award":["RETICS RD16\/0017\/0010"],"award-info":[{"award-number":["RETICS RD16\/0017\/0010"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>People with substance use disorders are considered at increased risk of COVID-19 and its more serious complications, however data on the impact of COVID-19 are lacking. The study aimed to describe the clinical characteristics and outcomes of COVID-19 on people with substance use disorders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>an observational study was carried out including patients aged \u2265 years with COVID-19 pneumonia admitted to an urban hospital during March 12 to June 21,2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 2078 patients admitted, 27 (1.3%) were people with substance use disorders: 23(85.2%) were men with a median age of 56.1 + 10.3 years and. The main SUD were alcohol in 18(66.7%) patients, heroine in 6(22.2%) and cocaine in 3(11.1%) and 24(88.8%) patients were on ongoing substance use disorder treatment. One or more comorbidities associated to COVID-19 risk were observed in 18(66.6%) of patients. During a median length of stay of 10 days (IQR:7-19), severe pneumonia developed in 7(25.9%) patients, acute respiratory distress syndrome in 5 (18.5%) and none died.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Larger sample sizes and sero-epidemiological studies are needed to confirm the low incidence of severe COVID-19 on patients with SUD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/pubmed\/fdaa181","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T19:19:53Z","timestamp":1600456793000},"page":"9-12","source":"Crossref","is-referenced-by-count":18,"title":["Clinical impact of COVID-19 on people with substance use disorders"],"prefix":"10.1093","volume":"43","author":[{"given":"G","family":"Vallecillo","sequence":"first","affiliation":[{"name":"Drug Addiction Unit, Institute of Neuropsychiatry and Addictions, Hospital del Mar, Parc de Salut Mar Consortium, Barcelona 08003, Spain"},{"name":"Hospital del Mar Medical Research Institute (IMIM), Barcelona 08003, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Perell\u00f3","sequence":"additional","affiliation":[{"name":"Emergency Department, Hospital Cl\u00ednic, Barcelona 09036, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"G\u00fcerri","sequence":"additional","affiliation":[{"name":"Hospital del Mar Medical Research Institute (IMIM), Barcelona 08003, Spain"},{"name":"Infectious Diseases Department, Hospital del Mar, Parc de Salut Mar Consortium, Barcelona 08003, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Drug Addiction Unit, Institute of Neuropsychiatry and Addictions, Hospital del Mar, Parc de Salut Mar Consortium, Barcelona 08003, Spain"},{"name":"Hospital del Mar Medical Research Institute (IMIM), Barcelona 08003, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Torrens","sequence":"additional","affiliation":[{"name":"Drug Addiction Unit, Institute of Neuropsychiatry and Addictions, Hospital del Mar, Parc de Salut Mar Consortium, Barcelona 08003, Spain"},{"name":"Hospital del Mar Medical Research Institute (IMIM), Barcelona 08003, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"issue":"13","key":"2021041306060698600_ref1","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72?314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"2021041306060698600_ref2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis","volume":"94","author":"Yang","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2021041306060698600_ref3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.15585\/mmwr.mm6912e2","article-title":"Severe outcomes among patients with coronavirus disease 2019 (COVID-19) \u2014 United States, February 12\u2013march 16, 2020","volume":"69","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"2021041306060698600_ref4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020","volume":"69","author":"Garg","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021041306060698600_ref5","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2020.07.024","article-title":"Characteristics and predictors of death among 4,035 consecutively hospitalized patients with COVID-19 in Spain","author":"Berenguer","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"2021041306060698600_ref6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/ph13070155","article-title":"Substance use disorder in the COVID-19 pandemic: a systematic review of vulnerabilities and complications","volume":"13","author":"Wei","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"2021041306060698600_ref7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7326\/M20-1212","article-title":"Collision of the COVID-19 and addiction epidemics","volume":"173","author":"Volkow","year":"2020","journal-title":"Ann Intern Med"},{"key":"2021041306060698600_ref8","volume-title":"COVID-19: Potential Implications for Individuals with Substance Use Disorders","author":"National Institue on Drug Abuse"},{"key":"2021041306060698600_ref9","volume-title":"The Implications of COVID-19 for People Who Use Drugs (PWUD) and Drug Service Providers","author":"European Monitoring Center for Drugs and Drug Addiction"},{"key":"2021041306060698600_ref10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/ADM.0000000000000260","article-title":"Alcohol, cannabis, and opioid use disorders, and disease burden in an integrated health care system","volume":"11","author":"Bahorik","year":"2017","journal-title":"J Addict Med"},{"key":"2021041306060698600_ref11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2296-10-25","article-title":"Chronic illness and multimorbidity among problem drug users: a comparative cross sectional pilot study in primary care","volume":"10","author":"Cullen","year":"2009","journal-title":"BMC Fam Pract"},{"key":"2021041306060698600_ref12","first-page":"23","article-title":"High prevalence and risks factors for non-communicable diseases in older people with opioid use disorder","volume":"22","author":"Vallecillo","year":"2020","journal-title":"HARCP"},{"key":"2021041306060698600_ref13","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113069","article-title":"COVID-19 pandemic: impact on psychiatric care in the United States, a review","volume":"289","author":"Bojdani","year":"2020","journal-title":"Psychiatry Res"},{"key":"2021041306060698600_ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00127-020-01924-7","article-title":"Early impacts of the COVID-19 pandemic on mental health care and on people with mental health conditions: framework synthesis of international experiences and responses","author":"Sheridan Rains","year":"2020","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"2021041306060698600_ref15","volume-title":"Pla d\u2019Acci\u00f3 sobre Drogues de Barcelona 2017-20","author":"Agencia de Salud P\u00fablica de Barcelona"},{"key":"2021041306060698600_ref16","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31483-5","article-title":"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study","author":"Poll\u00e1n","year":"2020","journal-title":"Lancet"},{"key":"2021041306060698600_ref17","volume-title":"Statistical Institute of Catalonia","author":"Catalan Health Survey"},{"key":"2021041306060698600_ref18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11739-020-02390-4","article-title":"Emergency department and out-of-hospital emergency system (112-AREU 118) integrated response to coronavirus disease 2019 in a northern Italy Centre","volume":"15","author":"Perlini","year":"2020","journal-title":"Intern Emerg Med"},{"key":"2021041306060698600_ref19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijid.2020.06.052","article-title":"Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis","volume":"98","author":"Kronbichler","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2021041306060698600_ref20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1360-0443.2008.02411.x","article-title":"Substance use disorder among older adults in the United States in 2020","volume":"104","author":"Han","year":"2009","journal-title":"Addiction"},{"issue":"1","key":"2021041306060698600_ref21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12954-020-00370-7","article-title":"Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic","volume":"17","author":"Dunlop","year":"2020","journal-title":"Harm Reduct J"},{"key":"2021041306060698600_ref22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/08897077.2020.1752351","article-title":"Opioid use disorder and the COVID 19 pandemic: a call to sustain regulatory easements and further expand access to treatment","volume":"41","author":"Green","year":"2020","journal-title":"Subst Abus"}],"container-title":["Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jpubhealth\/article-pdf\/43\/1\/9\/37029672\/fdaa181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jpubhealth\/article-pdf\/43\/1\/9\/37029672\/fdaa181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:13:59Z","timestamp":1618294439000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpubhealth\/article\/43\/1\/9\/5938409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,10,26]]},"published-print":{"date-parts":[[2021,4,12]]}},"URL":"https:\/\/doi.org\/10.1093\/pubmed\/fdaa181","relation":{},"ISSN":["1741-3842","1741-3850"],"issn-type":[{"value":"1741-3842","type":"print"},{"value":"1741-3850","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2020,10,26]]}}}